IDEXX Laboratories, Inc. $IDXX Shares Acquired by Vident Advisory LLC

Key Points

• Vident Advisory LLC increased its holdings in IDEXX Laboratories, Inc. by 35.3% in Q1, owning 2,745 shares worth approximately $1.15 million.
• IDEXX Laboratories reported Q2 earnings of $3.63 EPS, surpassing expectations, with revenues of $1.11 billion, reflecting a 10.6% year-over-year increase.
• Insider selling was noted as EVP Nimrata Hunt sold 7,143 shares for over $4.5 million, representing a 28.40% decrease in her ownership stake.

Vident Advisory LLC increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 35.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,745 shares of the company's stock after buying an additional 716 shares during the quarter. Vident Advisory LLC's holdings in IDEXX Laboratories were worth $1,153,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Sage Mountain Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 3.8% in the first quarter. Sage Mountain Advisors LLC now owns 635 shares of the company's stock valued at $267,000 after buying an additional 23 shares during the period. PDS Planning Inc grew its holdings in shares of IDEXX Laboratories by 3.9% in the 1st quarter. PDS Planning Inc now owns 641 shares of the company's stock worth $269,000 after acquiring an additional 24 shares during the last quarter. King Luther Capital Management Corp grew its holdings in shares of IDEXX Laboratories by 0.5% in the 1st quarter. King Luther Capital Management Corp now owns 4,896 shares of the company's stock worth $2,056,000 after acquiring an additional 24 shares during the last quarter. Bigelow Investment Advisors LLC grew its holdings in shares of IDEXX Laboratories by 1.9% in the 1st quarter. Bigelow Investment Advisors LLC now owns 1,420 shares of the company's stock worth $596,000 after acquiring an additional 27 shares during the last quarter. Finally, Wedbush Securities Inc. grew its holdings in shares of IDEXX Laboratories by 1.3% in the 1st quarter. Wedbush Securities Inc. now owns 2,145 shares of the company's stock worth $901,000 after acquiring an additional 28 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Trading Down 0.9%

IDEXX Laboratories stock opened at $633.95 on Thursday. The company's fifty day simple moving average is $588.74 and its 200-day simple moving average is $504.04. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12. The stock has a market cap of $50.72 billion, a P/E ratio of 52.79, a P/E/G ratio of 4.19 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same period in the previous year, the company posted $2.44 EPS. IDEXX Laboratories's revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Ratings Changes

IDXX has been the topic of a number of recent research reports. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, July 12th. BTIG Research lifted their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a report on Monday, August 4th. Piper Sandler restated a "neutral" rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Finally, Jefferies Financial Group initiated coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $649.44.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 7,143 shares of the firm's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total transaction of $4,503,161.49. Following the transaction, the executive vice president owned 18,007 shares in the company, valued at approximately $11,352,153.01. This trade represents a 28.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director M Anne Szostak sold 2,187 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the transaction, the director directly owned 262 shares in the company, valued at $169,600.46. This trade represents a 89.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock worth $34,293,468 over the last 90 days. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.